Security
PCSA · Processa Pharmaceuticals, Inc.
PCSANASDAQCommon stockCurrentCIK 1533743Updated Sep 26, 2026
Name history
Heatwurx, Inc. · through Oct 20, 2017
PCSA price & chart
Loading TradingView…
NASDAQ:PCSA on TradingView ↗About the company
We are a clinical-stage biopharmaceutical company developing a pipeline of Next Generation Cancer therapy (“NGC”) small molecules, two of which are in, or have completed, Phase 2 trials, and one is in pre-clinical development.
In the news
Recent filings
SCHEDULE 13G filing
10-Q filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Submission of Matters to a Vote of Security Holders
Items 5.02, 5.07, 9.01
Entry into a Material Definitive Agreement · Termination of a Material Definitive Agreement · Completion of Acquisition or Disposition of Assets · Unregistered Sales of Equity Securities · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Regulation FD Disclosure
Items 1.01, 1.02, 2.01, 3.02, 5.02, 5.03, 7.01, 9.01
4 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 7,813,567Source | 3,229,289Source | 5,786,643Source | 8,619,851Source |
| Property, Plant and Equipment, NetUSD | 3,812Source | 5,016Source | 2,554Source | — |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 5,536,955Source | 1,191,325Source | 4,706,197Source | 6,503,595Source |
| Assets, CurrentUSD | 5,670,874Source | 1,873,619Source | 5,632,497Source | 8,386,729Source |
| Prepaid Expense and Other Assets, CurrentUSD | 133,919Source | 682,294Source | 926,300Source | 1,883,134Source |
| Operating Lease, Right-of-Use AssetUSD | — | 70,677Source | 146,057Source | 227,587Source |
| Other Assets, NoncurrentUSD | — | — | 5,535Source | 5,535Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 2,236,253Source | 1,533,118Source | 797,484Source | 1,149,110Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 257Source | 371Source | 129Source | 1,614Source |
| Retained Earnings (Accumulated Deficit)USD | -100,783,033Source | -87,219,199Source | -75,369,081Source | -64,247,561Source |
| Stockholders' Equity Attributable to ParentUSD | 5,577,314Source | 1,696,171Source | 4,989,159Source | 7,470,741Source |
| Additional Paid in Capital, Common StockUSD | 106,660,090Source | 89,214,999Source | 80,658,111Source | 72,016,688Source |
| Liabilities and EquityUSD | 7,813,567Source | 3,229,289Source | 5,786,643Source | 8,619,851Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 2,236,253Source | 1,532,631Source | 730,579Source | 998,556Source |
| Operating Lease, Liability, CurrentUSD | — | 66,905Source | 83,649Source | 78,896Source |
| Accounts Payable, CurrentUSD | 1,056,796Source | 880,880Source | 311,617Source | 327,548Source |
| Operating Lease, Liability, NoncurrentUSD | — | — | 66,905Source | 150,554Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 1,179,457Source | 578,731Source | 146,274Source | 403,061Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 857,550Source | 629,514Source | 1,060,339Source | 8,828,713Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | 175,916Source | 569,263Source | -15,931Source | 108,643Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -11,385,195Source | -11,245,042Source | -8,063,346Source | -9,605,143Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -850,000Source | -3,244Source | -2,776Source | — |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | 3,244Source | 2,776Source | — |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 10,404Source | 15,902Source | — | 88,843Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 16,580,825Source | 7,733,414Source | 6,268,724Source | -388,843Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 4,345,630Source | -3,514,872Source | -1,797,398Source | -9,993,986Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 5,607Source | 1,204Source | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 857,550Source | 629,514Source | 2,371,214Source | — |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | — | 115,613Source |
| Amortization of Intangible AssetsUSD | — | — | — | 788,495Source |
| DepreciationUSD | 1,204Source | 782Source | 222Source | — |
| General and Administrative ExpenseUSD | 6,178,168Source | 4,782,060Source | 5,657,543Source | 8,763,058Source |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | — | — | — | 7,268,143Source |
| Investment Income, InterestUSD | 109,491Source | 201,088Source | 335,541Source | 101,202Source |
| Net Income (Loss) Attributable to ParentUSD | -13,563,834Source | -11,850,118Source | -11,121,520Source | -27,424,229Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -13,563,834Source | -11,850,118Source | -11,121,520Source | — |
| Operating Lease, ExpenseUSD | — | — | 81,530Source | 85,518Source |
| Proceeds from Issuance of Common StockUSD | 16,597,831Source | 7,763,079Source | 6,321,470Source | 6,400,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | — | — | — | 0Source |
| Operating Income (Loss)USD | -13,988,505Source | -12,051,206Source | -11,457,061Source | -27,525,431Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -13,563,834Source | -11,850,118Source | -11,121,520Source | -27,424,229Source |
| Net Income (Loss) Attributable to ParentUSD | -13,563,834Source | -11,850,118Source | -11,121,520Source | -27,424,229Source |
| Earnings Per Share, BasicUSD per share | -10.36Source | -3.87Source | -8.48Source | -1.7Source |
| Earnings Per Share, DilutedUSD per share | -10.36Source | -3.87Source | -8.48Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 1,309,271Source | 3,059,906Source | 1,311,572Source | 16,109,291Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 1,309,271Source | 3,059,906Source | 1,311,572Source | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | — | — | — | 788,495Source |
| General and Administrative ExpenseUSD | 6,178,168Source | 4,782,060Source | 5,657,543Source | 8,763,058Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -13,204,883Source | — | — | — |
| Investment Income, InterestUSD | 109,491Source | 201,088Source | 335,541Source | 101,202Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -13,563,834Source | -11,850,118Source | -11,121,520Source | — |
| Operating Lease, ExpenseUSD | — | — | 81,530Source | 85,518Source |
| Other IncomeUSD | 20,000Source | — | — | — |
| Research and Development ExpenseUSD | — | — | 5,799,518Source | 11,494,230Source |
Offerings
Registration 333-287997
- Gross proceeds
- 6998631.0
- Net proceeds
- 6508631.0
- Deal price
- 0.25
- Shares
- 27994524
- Offering price
- $0.2500
- Ticker
- PCSA
Registration 333-283986
- Net proceeds
- 4679679.0
- Deal price
- 0.615
- Offering price
- $0.61500
- Ticker
- PCSA
Filing attachments
ex99-1.htm · 8-K · 2026-07-29
EX-99.1 6 ex99-1.htm EX-99.1 Exhibit 99.1 PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC. AND APPROXIMATELY $200 MILLION CONCURRENT PRIVATE PLACEMENT TO ADVANCE BTK INHIBITOR, VT-7208, IN MULTIPLE DISEASE AREAS Acquisition brings into Processa’s pipeline Vidya’s lead asset, VT-7208, a next-generation, CNS-penetrant, once-daily, oral potentially best-in-class Bruton’s tyrosine kinase inhibitor (BTKi) designed to overcome the efficacy and safety limit…
Read attachment ↗ex99-1.htm · 8-K/A · 2025-08-14
EX-99.1 3 ex99-1.htm EX-99.1 Exhibit 99.1 Processa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies VERO BEACH, Fla., August 07, 2025 (GLOBE NEWSWIRE) - Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies for cancer patients, today announced that it has secured a strategic investment and that it is evaluating corporate cryptocurrency treasury strategies as …
Read attachment ↗ex99-1.htm · 8-K · 2025-08-07
EX-99.1 3 ex99-1.htm EX-99.1 Exhibit 99.1 Processa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies VERO BEACH, Fla., August 07, 2025 (GLOBE NEWSWIRE) - Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies for cancer patients, today announced that it has secured a strategic investment and that it is evaluating corporate cryptocurrency treasury strategies as …
Read attachment ↗ex99-1.htm · 8-K · 2025-07-01
EX-99.1 3 ex99-1.htm EX-99.1 Exhibit 99.1 Processa Pharmaceuticals Provides Portfolio and Business Update ● Signed binding term sheet granting Intact Therapeutics an exclusive option to license PCS12852 ● Continue enrolling patients in Phase 2 study of PCS6422 ● Strengthened balance sheet with $7M capital infusion VERO BEACH, Fla., July 1, 2025 (GLOBE NEWSWIRE) - Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage pharmaceutical company developing next-generation cancer ther…
Read attachment ↗ex4-1.htm · 8-K · 2025-06-18
EX-4.1 2 ex4-1.htm EX-4.1 Exhibit 4.1 COMMON STOCK PURCHASE WARRANT processa pharmaceuticals, inc. Warrant Shares: _______ Issue Date: _______, 2025 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Ini…
Read attachment ↗